<DOC>
	<DOCNO>NCT00189085</DOCNO>
	<brief_summary>In present study investigator research effect cholesterol absorption inhibitor ezetimibe postprandial lipemia postprandial endothelial function patient metabolic syndrome . The lipid-lowering effect high-dose statin monotherapy fast lipid equal combination therapy low-dose statin ezetimibe .</brief_summary>
	<brief_title>Effects Ezetimibe Postprandial Hyperlipidemia Endothelial Function</brief_title>
	<detailed_description>In patient high risk future cardiovascular event , intensive LDL cholesterol lower high dos statin therapy provide great protection death major cardiovascular event standard regimen . Intensive LDL cholesterol lower achieve high dose statin treatment combination therapy low dos statin ezetimibe . However , unclear whether combination therapy result beneficial effect cardiovascular prognosis . The metabolic syndrome cluster several vascular risk factor ( abdominal obesity , high blood pressure , hypertriglyceridemia , low HDL cholesterol high fast glucose ) . The underlie pathophysiology still fully clarify , insulin resistance seem main characteristic syndrome . Subjects metabolic syndrome increase risk development cardiovascular morbidity mortality type II diabetes . The prevalence metabolic syndrome high patient clinical manifestation vascular disease associate vascular damage patient . Insulin resistance link endothelial dysfunction decrease nitric oxide bioavailability several mechanism include , inflammation ( reflect elevate high sensitive C Reactive Protein ( hs-CRP ) plasma level ) , disruption insulin receptor signal cascade , increase production cytokine activation renin angiotensin system . However , study support association insulin resistance endothelial function , mechanism seem controversial . In postprandial state , insulin resistance associate hyperlipidemia . Postprandial hyperlipidemia may important determinant endothelial dysfunction well . Remnants chylomicron low density lipoprotein metabolism impair endothelial dependent vasodilatation . In line hypothesis endothelial function use surrogate endpoint cardiovascular morbidity , therapeutic modulation ( postprandial ) endothelial function may potentially contribute prevention cardiovascular disease patient metabolic syndrome . Statin therapy modulates ( postprandial ) endothelial function know whether indirect effect lipid-lowering direct vascular effect statins influence stability bioavailability NOS . AIMS In present study propose investigate effect cholesterol absorption inhibitor ezetimibe postprandial lipemia ( postprandial ) endothelial function patient metabolic syndrome . High-dose statin monotherapy lipid-lowering effect ( fast lipid ) combination therapy low dose statin ezetimibe . The latter may reduce postprandial lipemia effectively may therefore beneficial effect postprandial endothelial dysfunction . Ezetimibe unlikely direct vascular effect therefore observe change vascular function due change postprandial lipemia . As secondary objective study , enable u differentiate direct indirect effect statin therapy postprandial endothelial function compare modulation postprandial endothelial function monotherapy simvastatin combination therapy simvastatin ezetimibe . Hypothesis With comparable reduction fast plasma lipid , combination therapy low-dose statin ezetimibe reduce postprandial lipemia well high-dose statin monotherapy . This lead well postprandial endothelial function patient metabolic syndrome . Objectives 1 . To determine effect combination therapy low-dose statin ezetimibe postprandial hyperlipidemia compare high-dose statin monotherapy . 2 . To determine effect combination therapy low-dose statin ezetimibe postprandial endothelial ( dys- ) function compare high-dose statin monotherapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>1 . Male female ( postmenopausal ) patient , 1870 year age 2 . Diagnosis metabolic syndrome accord ATP III criterion ( 4 ) , include 3 follow metabolic abnormality : abdominal obesity ( waist circumference &gt; 102 cm men &gt; 88 cm woman ) elevate blood pressure ( ³ 130 mmHg systolic ³ 85 mmHg diastolic ) hypertriglyceridemia ( serum triglyceride ³ 1.70 mmol/L low highdensity lipoprotein ( HDL ) cholesterol ( serum HDLcholesterol &lt; 1.04 mmol/L men &lt; 1.29 mmol/L woman ) high fast glucose ( fast serum glucose ³ 6.1 mmol/L ) 3 . Written inform consent 1 . Smoking 2 . Thyroid disease ( TSH &gt; 5 mU/L clinical symptom hypothyroidism ) 3 . Hepatic disease ( ASAT ALAT &gt; 2 time upper limit normal ) 4 . Renal disease ( serum creatinine &gt; 1.7 time upper limit normal ) . 5 . A history coronary heart disease , cerebrovascular disease peripheral arterial disease . 6 . Use lipid lower therapy 7 . Systolic blood pressure ≥ 180 mmHg /or diastolic blood pressure ≥ 110 mmHg 8 . BMI &gt; 35 9 . HbA1c &gt; 6.5 % 10 . Triglycerides &gt; 8.0 mmol/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Metabolic syndrome</keyword>
</DOC>